Tesamorelin

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It has been modified to be more stable than the native hormone while retaining activity at the GHRH receptor. Published reviews describe it as a human growth hormone releasing factor analogue, and research has examined its role in endogenous GHRH signaling and its association with visceral adipose tissue. It is supplied by CoreX for laboratory research use only.

Research describes tesamorelin as acting on the GHRH receptor (GHRH-R) at the pituitary, the same target as the native releasing hormone. Its structural modifications are intended to give it greater stability than endogenous GHRH. Studies have focused on this pituitary action and on downstream metabolic signaling, including effects associated with growth hormone release and changes in body composition markers such as visceral fat.

The best-documented research area is HIV-associated lipodystrophy, where reviews describe tesamorelin's study in relation to visceral adipose tissue. Research has also examined associated metabolic markers and the broader question of muscle preservation within body-composition work. More recent reviews in orthopaedic and sports medicine literature discuss tesamorelin alongside other injectable peptides, while noting that evidence in those settings is more limited than in its primary clinical research area.

Clinical reviews of tesamorelin discuss its adverse event profile from human studies, but those findings are not summarized on this page. Human safety data outside controlled clinical research, including for research-grade material, are limited. Reviews of approved and unapproved peptide therapies in musculoskeletal and athletic contexts have highlighted safety and efficacy as areas where further evidence is needed. Findings from specific trial populations should not be generalized to other settings.

Research protocols have used 500 to 2,000 mcg per administration, given once daily before sleep by the subcutaneous route, in 8-week blocks followed by 4 weeks off. These figures describe what research protocols have used and are not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference, and the compound is sold for research use only.